Drug Manufacture MorphoSys Awaits Pivotal Phase 3 Clinical DataBy MohamedMis2July 11, 2023 In a highly anticipated move, JP Morgan analyst Michael Nuen suggests that MorphoSys, the German biotech company, could experience a…
